Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

OBJECTIVE: To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial. METHODS: Patients received adalimuma...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, D, Schiff, M H, Sieper, J, Kivitz, A J, Wong, R L, Kupper, H, Dijkmans, B A C, Mease, P J, Davis, J C
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2008
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674550/
https://www.ncbi.nlm.nih.gov/pubmed/18701556
http://dx.doi.org/10.1136/ard.2007.087270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674550/
https://www.ncbi.nlm.nih.gov/pubmed/18701556
http://dx.doi.org/10.1136/ard.2007.087270

Ejemplares similares